Physician profile
Brian J Heller
NPI 1942391784
$5,670.10
in general payments reported to CMS, 2019-2025
57 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $445 · 2021: $699 · 2022: $740 · 2023: $615 · 2024: $1,139 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.60 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $610.99 | 2019-2025 | |
| Genentech USA, INC. | $407.47 | 2019-2025 | Tecentriq, Phesgo, Itovebi |
| Celgene Corporation | $374.87 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $308.65 | 2019-2024 | Enhertu, Calquence, Lynparza |
| Astellas Pharma US INC | $264.24 | 2019-2025 | Padcev, Xospata, Xtandi |
| Merck Sharp & Dohme LLC | $261.86 | 2019-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $259.56 | 2022-2025 | Enhertu, Datroway |
| Eisai INC. | $252.83 | 2019-2025 | |
| Amgen INC. | $214.16 | 2019-2022 | |
| Beigene USA, INC. | $187.80 | 2020-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $185.67 | 2021-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $173.33 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $168.45 | 2019-2024 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $150.31 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $137.70 | 2024-2025 | Onivyde, Somatuline Depot |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.